β1-Receptor Blockade for Chronic Mitral Regurgitation - β1-Receptor Blockade for Chronic Mitral Regurgitation
Description:
The goal of the trial was to evaluate treatment with beta-blockade compared with placebo among patients with moderate to severe mitral regurgitation.
Hypothesis:
Beta-blockade will attenuate left ventricular (LV) remodeling and preserve systolic function.
Study Design
- Placebo Controlled
- Randomized
- Blinded
- Parallel
Patient Populations:
- Patients with moderate to severe mitral regurgitation
- LVEF >55%
- LV end-systolic dimension <40 mm
- Echocardiographic thickening of mitral valve leaflets and prolapse
Number of enrollees: 38
Duration of follow-up: 2 years
Mean patient age: 53 years
Percentage female: 58%
Ejection fraction: 62%
New York Heart Association (NYHA) class: 100% with functional class I or II
Exclusions:
- Patients with New York Heart Association functional class III or IV symptoms
- Prior myocardial infarction or significant coronary artery disease
- Valvular disease other than mitral
- Renal insufficiency
- Hypertension
Primary Endpoints:
- Change in LV EDV/BSA
- Change in LV ED mass /LV EDV
- Change in LV ED radius/wall thickness
- Change in LV EF
- Change in LV ESV/BSA
- Change in peak systolic longitudinal strain rate
- Change in peak early filling rate
Drug/Procedures Used:
Asymptomatic patients with moderate to severe mitral regurgitation were randomized to metoprolol succinate (Toprol XL) 25-100 mg daily (n = 19) versus placebo (n = 19) for 2 years. Metoprolol succinate was titrated every 2 weeks to a maximum of 100 mg daily. Cardiac magnetic resonance imaging (MRI) was performed at baseline, and 6, 12, 18, and 24 months.
Principal Findings:
Overall, 38 patients were randomized. The mean age was 53 years, 58% were women, mean blood pressure was 125/75 mm Hg, mean heart rate was 66 bpm, and mean ejection fraction (EF) was 62%. No patient had atrial fibrillation.
At 2 years, there was no change in LV end-diastolic volume/body surface area (EDV/BSA), LV ED mass/LV EDV, LV ED radius/wall thickness, LV end-systolic volume/BSA, and peak systolic longitudinal strain rate for beta-blockade versus placebo.
However, at 2 years there was a benefit favoring beta-blockade for LVEF (p = 0.0060), and peak early filling rate (p = 0.0011).
Interpretation:
In this small pilot trial, in patients with asymptomatic moderate to severe mitral regurgitation, 2 years of beta-blockade treatment prevented progressive decline in LVEF compared with placebo. However, beta-blockade did not prevent parameters of LV remodeling. A large multicenter trial appears warranted.
References:
Ahmed MI, Aban I, Lloyd SG, et al. A Randomized Controlled Phase IIb Trial of β1-Receptor Blockade for Chronic Mitral Regurgitation. J Am Coll Cardiol 2012;Jul 18:[Epub ahead of print].
Keywords: Body Surface Area, Follow-Up Studies, Mitral Valve Insufficiency, Stroke Volume, Blood Pressure, Metoprolol, Heart Rate, Magnetic Resonance Imaging
< Back to Listings